HCV Treatment
CROI 2015: Hepatitis C -- A Light at the End of the Tunnel [VIDEO]
- Details
- Category: HCV Treatment
- Published on Monday, 23 February 2015 00:00
- Written by Gregory Fowler
Charles Rice from the Rockefeller University traced the development of scientific knowledge about hepatitis C virus and the evolution of its treatment in a plenary lecture at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) taking place this week in Seattle.
CROI 2015: Retrovirus Conference Now Underway in Seattle
- Details
- Category: HIV Treatment
- Published on Monday, 23 February 2015 00:00
- Written by HIVandHepatitis.com
The 2015 Conference on Retroviruses and Opportunistic Infections (CROI) takes place this week, February 23-26, at the Washington State Convention Center in Seattle. CROI focuses on HIV treatment, prevention, and basic science. For the past several years it has also included substantial hepatitis C content, and this year will feature presentations on Ebola virus. HIVandHepatitis.com is on site in Seattle all week bringing you news coverage and Twitter updates (@HIVandHepatitis).
AbbVie Dual Regimen Highly Effective Against HCV Genotype 1b
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 20 February 2015 00:00
- Written by AbbVie
A 2-drug combination consisting of AbbVie's ritonavir-boosted HCV protease inhibitor parataprevir and NS5A inhibitor ombitasvir -- part of the Viekira Pak regimen -- demonstrated a 95% cure rate for people with hepatitis C virus genotype 1b, the most common type in Japan, according to a recent company announcement.
CROI 2015: Retrovirus Conference Starts Monday in Seattle
- Details
- Category: HIV Treatment
- Published on Friday, 20 February 2015 00:00
- Written by HIVandHepatitis.com
The 2015 Conference on Retroviruses and Opportunistic Infections (CROI) takes place next week, February 23-26, at the Washington State Convention Center in Seattle. CROI focuses on HIV treatment, prevention, and basic science. For the past several years it has also included substantial hepatitis C content, and this year will feature presentations on Ebola virus. HIVandHepatitis.com will be on site in Seattle all week bringing you news coverage and Twitter updates (@HIVandHepatitis).
Achillion's ACH-3102 + Sofosbuvir for 6 Weeks Shows 100% Cure Rate
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 11 February 2015 00:00
- Written by Achillion
Achillion's next-generation HCV NS5A inhibitor ACH-3102 plus Gilead Science's HCV polymerase inhibitor sofosbuvir (Sovaldi) taken for 6 weeks led to sustained virological response in all previously untreated genotype 1 hepatitis C patients in a small Phase 2 trial, according to a recent company announcement. Achillion now plans to test this same combination taken for just 4 weeks.
Web Design and Development by